Portal de Periódicos da CAPES

A Review of the New Angiotensin II‐Receptor Antagonist Irbesartan

1998; Wiley; Volume: 16; Issue: 3 Linguagem: Inglês

10.1111/j.1527-3466.1998.tb00354.x

1527-3466

J.R. Powell, Richard A. Reeves, Maria Rosaria Marino, Catherine Cazaubon, Dino Nisato,

Blood Pressure and Hypertension Studies

Cardiovascular Drug ReviewsVolume 16, Issue 3 p. 169-194 Free Access A Review of the New Angiotensin II-Receptor Antagonist Irbesartan James R. Powell, Corresponding Author James R. Powell Bristol-Myers Squibb, Princeton, NJ, USAAddress reprint requests and correspondence to Dr. J. R. Powell, Cardiovascular Drug Discovery, Bristol-Myers Squibb, P.O. Box 4000, Princeton, NJ, USA 08543-4000. Fax: 609-252-3219.Search for more papers by this authorRichard A. Reeves, Richard A. Reeves Bristol-Myers Squibb, Princeton, NJ, USASearch for more papers by this authorMaria R. Marino, Maria R. Marino Bristol-Myers Squibb, Princeton, NJ, USASearch for more papers by this authorCatherine Cazaubon, Catherine Cazaubon Cardiovascular Research Department, Sanofi Recherche, Montpellier, FranceSearch for more papers by this authorDino Nisato, Dino Nisato Cardiovascular Research Department, Sanofi Recherche, Montpellier, FranceSearch for more papers by this author James R. Powell, Corresponding Author James R. Powell Bristol-Myers Squibb, Princeton, NJ, USAAddress reprint requests and correspondence to Dr. J. R. Powell, Cardiovascular Drug Discovery, Bristol-Myers Squibb, P.O. Box 4000, Princeton, NJ, USA 08543-4000. Fax: 609-252-3219.Search for more papers by this authorRichard A. Reeves, Richard A. Reeves Bristol-Myers Squibb, Princeton, NJ, USASearch for more papers by this authorMaria R. Marino, Maria R. Marino Bristol-Myers Squibb, Princeton, NJ, USASearch for more papers by this authorCatherine Cazaubon, Catherine Cazaubon Cardiovascular Research Department, Sanofi Recherche, Montpellier, FranceSearch for more papers by this authorDino Nisato, Dino Nisato Cardiovascular Research Department, Sanofi Recherche, Montpellier, FranceSearch for more papers by this author First published: 02 April 2007 https://doi.org/10.1111/j.1527-3466.1998.tb00354.xCitations: 18AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 AVAPRO® package insert. Princeton , NJ : Bristol-Myers Squibb Company; 1998. 2 Bauer JH. Angiotensin-converting enzyme inhibitors. Am J Hypertens 1990; 3: 331– 337. 3 Bauer JH, Reams GP. The angiotensin-II type-1 receptor antagonists: A new class of antihypertensive drugs. Arch Intern Med 1995; 155: 1361– 1368. 4 Belcher G, Hubner R, George M, Elmfeldt D, Lunde H. Candesartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 11(Suppl. 2): S85– S89. 5 Bernhart CA, Perreaut PM, Ferrari BP, et al. A new series of imidazolones: Highly specific and potent nonpeptide AT1 angiotensin II-receptor antagonists. J Med Chem 1993; 36: 3371– 3380. 6 Brunner HR. The new angiotensin II-receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 1997; 10: 311S– 317S. 7 Burnier M, Hagman M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II-receptor blockade in healthy subjects. Hypertension 1995; 25: 602– 609. 8 Casas A, Merlos M. Castaner J. Irbesartan. Drugs Fut 1997; 22: 481– 491. 9 Cazaubon C, Gougat J, Bousquet F, et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II-receptor antagonist. J. Pharmacol Exp Ther 1993; 265: 826– 834. 10 Cazaubon C, Lacour C, Richaud JP, Segondy D, Canals F, Nisato D. Effects of AT1-receptor blockade on angiotensin II-induced plasma catecholamines, aldosterone, renin activity, and vasopressin responses in conscious rats. Br J Pharmacol 1994; 113(Suppl): 50P. 11 Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998; 26: 408– 417. 12 Chen S-J, Osbakken MD, Chen Y-F, Allen L, Durand JN, Oparil S. Angiotensin II Type I (AT1) receptor-antagonist irbesartan and estrogen have profound but nonadditive inhibitory effects on neointima formation in balloon injured carotid arteries of ovariectomized rats. Circulation 1997; 96(Suppl. I): I-608. 13 Chiu AT, Herblin WF, McCall DE, et al. Identification of angiotensin II-receptor subtypes. Biochem Biophys Res Commun 1989; 165: 196– 203. 14 Chiu AT, McCall DE, Nguyen TT, et al. Discrimination of angiotensin II receptor subtypes of dithiothreitol. Eur J Pharmacol 1989; 170: 117– 118. 15 Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II-receptor antagonist, to normal volunteers: Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333– 1342. 16 Christophe B, Libon R, Cazaubon C, Nisato D, Manning A, Chatelain P. Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: Potential mechanisms of action. Eur J Pharmacol 1995; 281: 161– 171. 17 Curzen NP, Fox KM. Do ACE inhibitors modulate atherosclerosis Eur Heart J 1997; 18: 1530– 1535. 18 de Gasparo M, Husain A, Alexander W, et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 25: 924– 927. 19 Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438– 445. 20 Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: Target for drug research J Hypertens 1994; 12(Suppl. 2): S1– S5. 21 Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511– 1518. 22 Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ. Angiotensin converting-enzyme inhibition in patients with congestive heart failure. Circulation 1978; 58: 770– 776. 23 Gielsdorf W, Mangold B, Marino MR. Pharmacodynamics and pharmacokinetics of warfarin given with irbesartan. Clin Pharmacol Ther 1998; 63: 228. 24 Goldberg A, Sweet C. Efficacy and safety of losartan. Can J Cardiol 1995; 11(Suppl. F): 27F– 32F. 25 Herbert J-M, Delisée C, Dol F, et al. Effect of SR 47436, a novel angiotensin II AT1-receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994; 251: 143– 150. 26 Himmelmann A, Svensson A, Bergbrant A, Hansson L. Losartan in essential hypertension: Long-term effects on blood pressure and left ventricular mass. J Hypertens 1996; 14(Suppl. 1): S215. 27 Hope S, Brecher P, Chobanian AV. Comparison of the effects of AT1-receptor blockade and ACE inhibition on atherosclerosis. Am J Hypertens 1998, in press. 28 Jackson DG, Jones HB. Histopathological and ultrastructural changes in the juxtaglomerular apparatus of the rat following administration of ZENECA ZD6888 (2-ethyl-5,6,7,8-tetrahydro-4-[(2′-(1H-tetrazol-5-yl)biphenyl-4-yl)-methoxy]quinoline), an angiotensin II antagonist. Toxicol Pathol 1995; 23: 7– 15. 29 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413– 2446. 30 Jover B, Cazaubon C, Dupont M, Nisato D, Mimran A. Systemic and renal adaptation to sodium restriction in the rat: influence of a new nonpeptide angiotensin II-receptor antagonist, SR 47436. Circulation 1992; 86: 545. 31 Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II-receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998; 11: 445– 453. 32 Lacour C, Canals C, Cazaubon C, Nisato D. Central effects of irbesartan, an AT1 antagonist in rats. Pharmacol Res 1995; 31(Suppl.): 326. 33 Lacour C, Canals F, Galindo G, Cazaubon C, Segondy D, Nisato D. Efficacy of SR 47436 (BMS-18695), a non-peptide angiotensin AT1-receptor antagonist in hypertensive rat models. Eur J Pharmacol 1994; 264: 307– 316. 34 Lacour C, Roccon A, Cazaubon C, Segondy D, Nisato D. Pharmacological study of SR 47436, a non-peptide angiotensin II AT1-receptor antagonist, in conscious monkeys. J Hypertens 1993; 11: 1187– 1194. 35 Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387– 1393. 36 Larochelle P, Flack JM, Marbury TC, Sareli P, Krieger EM, Reeves RA. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613– 1615. 37 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456– 1462. 38 Littlejohn T, Saini RK, Badiak H, Beagan M, Kassler-Taub K, Freitag S. Long-term safety and antihypertensive efficacy of irbesartan, the angiotensin II-receptor antagonist: pooled results of six open-label studies. Am J Hypertens 1997; 10. 39 Marino MR, Hammett JL, Ferreira I, Ford NF, Uderman HD. Lack of effect of nifedipine on the pharmacokinetics of irbesartan in healthy male subjects. J Clin Pharmacol 1997; 37: 872. 40 Marino MR, Langenbacher K, Ford NF, Uderman HD. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998; 38: 246– 255. 41 Marino MR, Langenbacher KM, Ford NF, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin-II blocker irbesartan. Clin Drug Invest 1997; 14: 383– 391. 42 Marino MR, Langenbacher KM, Ford NF, Uderman HD. Safety, tolerability. pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects. Clin Pharmacol Ther 1997; 61: 207. 43 Marino MR, Langenbacher KM, Raymond RH, Ford NF, Lasseter KC. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998; 38: 347– 356. 44 Marino MR, Langenbacher KM, Raymond RH, Whigan D, Ford NF. Pharmacokinetics (PK) and antihypertensive effects of irbesartan (an All-receptor antagonist) in subjects with hypertension. J Hypertens 1996; 14: S348. 45 Michel JB, Wood JM, Hofbauer KG, Corvol P, Menard J. Blood pressure effects of renin inhibition by human renin antiserum in normotensive marmosets. Am J Physiol 1984; 246: F309– F316. 46 Mimran A, Ribstein J. Angiotensin converting-enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am J Hypertens 1994; 7: 73S– 81S. 47 Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan. an angiotensin II-receptor antagonist. Clin Pharmacol Ther 1992; 51: 513– 521. 48 Nakajima M, Hutchinson HG, Fujinaga M. et al. The angiotensin-II type-2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92: 10663– 10667. 49 Owen RA, Molon-Noblot S, Hubert MF, Kindt MV, Keenan KP, Eydelloth RS. The morphology of juxtaglomerular cell hyperplasia and hypertrophy in normotensive rats and monkeys given as angiotensin II receptor antagonist. Toxicol Pathol 1994; 22: 606– 619. 50 Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747– 752. 51 Pool JL, Guthrie RM, Littlejohn TW III, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462– 470. 52 Powell JR, Marino MR, Coniglio AA. A model to predict clinical efficacy of angiotensin II blocker (AIIB). J Clin Pharmacol 1997; 37: 871. 53 Reeves RA, Lin C-S, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: An integrated analysis. Hypertension 1998; 31: 1311– 1316. 54 Ribstein J, Picard A, Armagnac C, Bouroudian M, Sissmann J, Mimran A. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects. J Hypertens 1997; 15(Suppl. 4): S117. 55 Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A. Effects of the angiotensin-II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens 1994; 12: 131. 56 Richer-Giudicelli C, Fornes P, Cazaubon C, Nisato D, Giudicelli J-F. Effects of angiotensin II AT1 receptor blockade on survival, systemic, and coronary hemodynamics and cardiac remodeling in post-ischemic heart failure in rats. Circulation 1997; 96(8 Suppl.): 1644. 57 Robertson MJ, Dougall IG, Harper D, McKechnie KC, Leff P. Agonist-antagonist interactions at angiotensin receptors: Application of a two-state receptor model. Trends Pharmacol Sci 1994; 15: 364– 369. 58 Roccon A, Marchionni D, Donat F, Segondy D, Cazaubon C, Nisato D. A pharmacodynamic study of SR 47436, a selective AT, receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br J Pharmacol 1994; 111: 145– 150. 59 Sica DA, Marino MR, Hammett JL, Ferreira I, Gehr TWB, Ford NF. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997; 62: 610– 618. 60 Siegl PKS. Discovery of losartan, the first specific non-peptide angiotensin II-receptor antagonist. J Hypertens 1993; 11(Suppl. 3): S19– S22. 61 Simon SR, Black HR, Moser M, Berland WE. Cough and ACE inhibitors. Arch Intern Med 1992; 152: 1698– 1700. 62 Simon TA, Gelarden T, Freitag SA, Kassler-Taub KB, Davies R. Safety of irbesartan in the treatment of mild to moderate systemic hypetension. Am J Cardiol 1998; 82: 179– 182. 63 Takase K, Ikuse T, Aono H, Okahara A. Toxicity study of the angiotensin converting-enzyme inhibitor rentiapril in rats. Arzneimittelforschung 1995; 45: 15– 18. 64 Teerlink JR. Neurohumoral mechanisms in heart failure: A central role for the renin-angiotensin system. J Cardiovasc Pharmacol 1996; 27(Suppl. 2): S1– S8. 65 Vacher E, Fornes P, Richer C, Bruneval P, Nisato D, Guidicelli J-F. Early and late haemodynamic and morphological effects of angiotensin II subtype I receptor blockage during genetic hypertension development. J Hypertens 1995; 13: 675– 682. 66 Vachharajani N, Chang S-Y, Shyu WC, Greene D, Barbhaiya R. Absolute bioavailability of irbesartan, an angiotensin II-receptor antagonist, in man. Pharm Res 1995; 12: S418. 67 Vachharajani N, Shyu WC, Greene D, Barbhaiya R. The effect of age on the pharmacokinetics of irbesartan. J Clin Pharmacol 1997; 37: 872. 68 Vachharajani N, Shyu WC, Smith R, Chang S-Y, Greene D, Barbhaiya R. The effects of age and gender on the pharmacokinetics of irbesartan. Pharm Res 1995; 12: S388. 69 Vachharajani NN, Shyu WC, Mantha S, Park J-S, Greene DS, Barbhaiya RH. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J Clin Pharmacol 1998; 38: 443– 446. 70 van den Meiracker AH, Admiraal PJJ, Janssen JA, et al. Hemodynamic and biochemical effects of the AT1 receptor-antagonist irbesartan in hypertension. Hypertension 1995; 25: 22– 29. 71 Waeber B, Brunner HR. Angiotensin II-antagonists: A new class of antihypertensive agent. Br J Clin Pract 1996; 50: 265– 268. 72 Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin II-receptor subtypes. Biochem Biophys Res Commun 1989; 163: 284– 291. 73 Ziai F, Ots M, Provoost AP, et al. The angiotensin receptor-antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney hit 1996; 50(Suppl. 57): S132– S136. Citing Literature Volume16, Issue3September 1998Pages 169-194 ReferencesRelatedInformation